1. Home
  2. AYTU vs RDHL Comparison

AYTU vs RDHL Comparison

Compare AYTU & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.57

Market Cap

25.7M

Sector

Health Care

ML Signal

HOLD

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$0.81

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AYTU
RDHL
Founded
N/A
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.7M
3.8M
IPO Year
2015
2012

Fundamental Metrics

Financial Performance
Metric
AYTU
RDHL
Price
$2.57
$0.81
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$9.33
N/A
AVG Volume (30 Days)
42.6K
22.3K
Earning Date
05-13-2026
11-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,632,080.00
N/A
Revenue This Year
N/A
$381.91
Revenue Next Year
$43.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
277.47
N/A
52 Week Low
$0.96
$0.71
52 Week High
$3.07
$3.31

Technical Indicators

Market Signals
Indicator
AYTU
RDHL
Relative Strength Index (RSI) 49.70 40.98
Support Level $2.46 $0.80
Resistance Level $2.66 $0.90
Average True Range (ATR) 0.10 0.05
MACD -0.01 0.01
Stochastic Oscillator 33.07 49.97

Price Performance

Historical Comparison
AYTU
RDHL

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Share on Social Networks: